Do endothelin A receptor and RAGE antibodies indicate neurovascular signaling or disease activity?

Endothelin-A (ETA) and RAGE are biologically credible neurovascular targets, but the evidence differs sharply between receptor biology and the clinical interpretation of antibodies against them.

Established vascular and endothelial biology

• ETA signaling directly regulates vasoconstriction. In isolated human cerebral arteries, endothelin-1 caused concentration-dependent contraction that was significantly inhibited by the selective ETA antagonist FR139317. ETA receptors are present in cortical resistance vessels and small pial arteries. Downstream phospholipase-C activation, intracellular Ca²⁺ mobilization, calcium entry, and depolarization support sustained vascular-smooth-muscle contraction; ETA signaling in cerebral pericytes may also narrow capillaries.
• RAGE activation promotes inflammatory endothelial dysfunction. In brain endothelial models, amyloid-β–RAGE engagement activates NF-κB and oxidative/inflammatory signaling, increasing inflammatory cytokine production. RAGE also mediates blood-to-brain amyloid-β transport, providing a potential feed-forward neurovascular mechanism.

Blood–brain barrier mechanisms

• In brain endothelial cells, amyloid-β–RAGE signaling reduced the tight-junction proteins ZO-1, claudin-5, and occludin and increased permeability. Anti-RAGE antibody prevented amyloid-β-induced permeability and ZO-1 disruption in bEnd.3 cells. These are direct mechanistic findings, but they remain principally cell-model evidence rather than proof of human clinical causality.

Antibody interpretation and clinical implications

• ETA-receptor autoantibodies have shown agonistic activity experimentally, so functionally active antibodies could conceivably influence vascular signaling. In contrast, functional effects of RAGE antibodies are not established.
• A positive ETA- or RAGE-antibody binding result does not demonstrate receptor activation, CNS/neurovascular tissue access, or causation of cognitive or vascular symptoms. Interpretation requires phenotype concordance, assay confirmation, titer and compartment context, and supportive imaging or CSF findings.

Bottom line

• ETA and RAGE signaling plausibly contribute to neurovascular constriction, inflammation, and barrier injury, but antibody positivity alone is not evidence of pathogenic disease activity and should not, by itself, direct antibody-targeted treatment.